Open Access
Review
The aspartyl (asparaginyl) beta-hydroxylase in carcinomas
Hui Yang1,2,*,Jing Li1,2,Ruihua Tang1,2,Ji Li1,2,Yaxiong Liu1,2,Linjie Ye1,2,Dongyan Shao1,2,Mingliang Jin1,2,Qingsheng Huang1,2,Junlin Shi1,2
1
School of Life Sciences, Northwestern Polytechnical University, 710072 Xi’an, China
2
Key Laboratory for Space Bioscience and Biotechnology, Northwestern Polytechnical University, 710072 Xi’an, China
DOI: 10.2741/4344 Volume 20 Issue 5, pp.902-909
Published: 01 January 2015
(This article belongs to the Special Issue Pathogenesis and diagnostic modalities in cancer)
*Corresponding Author(s):  
Hui Yang
E-mail:  
kittyyh@sina.cn
Abstract

Aspartyl-(asparaginyl)-β-hydroxylase (AAH) is a member of the α-ketoglutarate-dependent dioxygenase family that catalyzes the hydroxylation of aspartyl and asparaginyl residues epidermal growth factor (EGF)-like domains of protein. In human tumorous cell lines from main systems of body, including tumor cells of kidney, throat, breast, liver, bladder, cervical and ovary, the AAH can be detected at both the transcriptional level and the translational level, and moreover, the AAH expression is usually increased, which is associated with the development and progression of carcinomas. Thus, AAH may play an important role in different carcinomas and may be a potential hub in carcinogenesis. In this review, we will discuss the role of AAH in carcinomas, focusing on liver cancers and other digestive tumors, lung cancers, and tumors of nervous system.

Key words
hepatocellular carcinoma,AAH,ICAMs,LFA-1,PI3K,Review
Share and Cite
Hui Yang, Jing Li, Ruihua Tang, Ji Li, Yaxiong Liu, Linjie Ye, Dongyan Shao, Mingliang Jin, Qingsheng Huang, Junlin Shi. The aspartyl (asparaginyl) beta-hydroxylase in carcinomas. Frontiers in Bioscience-Landmark. 2015. 20(5); 902-909.